UBS Group
MGRX icon

UBS Group’s Mangoceuticals MGRX Stock Holding History

UBS Group’s Portfolio MGRX Stock Details MGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-46,167
Closed -$34.2K – 10912
2025
Q4 		$34.2K Buy
46,167
+46,164
+1,538,800% +$74.9K ﹤0.01% 7450
2025
Q3 		$7 Sell
3
-76
-96% -$142 ﹤0.01% 10215
2025
Q2 		$120 Sell
79
-7,431
-99% -$13.9K ﹤0.01% 9988
2025
Q1 		$14.6K Buy
7,510
+5,986
+393% +$21.5K ﹤0.01% 8418
2024
Q4 		$3.69K Buy
+1,524
New +$3.99K ﹤0.01% 8839
2024
Q3 		– Sell
-3,530
Closed -$16.1K – 9855
2024
Q2 		$16.1K Buy
3,530
+2,567
+267% +$11.9K ﹤0.01% 7447
2024
Q1 		$3.13K Buy
+963
New +$3.83K ﹤0.01% 7770
2023
Q4 		– Sell
-4
Closed -$50 – 9667
2023
Q3 		$50 Sell
4
-13
-76% -$243 ﹤0.01% 9001
2023
Q2 		$456 Sell
17
-294
-95% -$5.79K ﹤0.01% 8227
2023
Q1 		$5.32K Buy
+311
New +$11K ﹤0.01% 8053

Other funds holding MGRX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
ACA
Ackerman Capital Advisors Dallas, Texas $497M AUM 16.31% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

UBS Group's MGRX Position: Q1 2026 in Review

UBS Group sold out of Mangoceuticals (MGRX) in Q1 2026, closing a stake of 46,167 shares — an estimated $34.2K sold.

UBS Group first reported a position in MGRX in Q1 2023 and held it in 10 quarters. The position peaked at $34.2K in Q4 2025. 18 funds tracked by Wall St. Rank hold MGRX as of Q1 2026.

  • UBS Group reported no remaining Mangoceuticals position as of Q1 2026 after selling out during the quarter.
  • UBS Group sold 46,167 Mangoceuticals shares in Q1 2026, an estimated $34.2K.
  • UBS Group first reported a position in Mangoceuticals in Q1 2023 and held it in 10 quarters.
  • UBS Group's Mangoceuticals position peaked at $34.2K in Q4 2025.
  • 18 funds tracked by Wall St. Rank held Mangoceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.